38 related articles for article (PubMed ID: 11803262)
1. Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer.
Sartor O; Weinberger M; Moore A; Li A; Figg WD
Urology; 1998 Aug; 52(2):252-6. PubMed ID: 9697790
[TBL] [Abstract][Full Text] [Related]
2. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response.
Tannock I; Gospodarowicz M; Meakin W; Panzarella T; Stewart L; Rider W
J Clin Oncol; 1989 May; 7(5):590-7. PubMed ID: 2709088
[TBL] [Abstract][Full Text] [Related]
3. An exploratory first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2- and 1-week interval in patients with metastatic castration resistant prostate cancer.
Vrouwe JPM; Kamerling IMC; van Esdonk MJ; Metselaar JM; Stuurman FE; van der Pluijm G; Burggraaf J; Osanto S
Pharmacol Res Perspect; 2021 Oct; 9(5):e00845. PubMed ID: 34414692
[TBL] [Abstract][Full Text] [Related]
4. Metronomic chemotherapy with cyclophosphamide plus low dose of corticosteroids in advanced castration-resistant prostate cancer across the era of taxanes and new hormonal drugs.
Calvani N; Morelli F; Naglieri E; Gnoni A; Chiuri VE; Orlando L; Fedele P; Cinieri S
Med Oncol; 2019 Aug; 36(9):80. PubMed ID: 31399784
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D in prostate cancer.
Trump DL; Aragon-Ching JB
Asian J Androl; 2018; 20(3):244-252. PubMed ID: 29667615
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor reverts dexamethasone‑induced inhibition of prostate cancer cell proliferation and migration.
Guo J; Ma K; Xia HM; Chen QK; Li L; Deng J; Sheng J; Hong YY; Hu JP
Mol Med Rep; 2018 Apr; 17(4):5887-5893. PubMed ID: 29436611
[TBL] [Abstract][Full Text] [Related]
7. Comparing the rules of engagement of androgen and glucocorticoid receptors.
Claessens F; Joniau S; Helsen C
Cell Mol Life Sci; 2017 Jun; 74(12):2217-2228. PubMed ID: 28168446
[TBL] [Abstract][Full Text] [Related]
8. The role of glucocorticoid receptor in prostate cancer progression: from bench to bedside.
Hu J; Chen Q
Int Urol Nephrol; 2017 Mar; 49(3):369-380. PubMed ID: 27987128
[TBL] [Abstract][Full Text] [Related]
9. [Corticosteroids in the management of advanced prostate cancer].
Kübler H
Urologe A; 2017 Feb; 56(2):217-223. PubMed ID: 27878318
[TBL] [Abstract][Full Text] [Related]
10. Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients.
Di Desidero T; Derosa L; Galli L; Orlandi P; Fontana A; Fioravanti A; Marconcini R; Giorgi M; Campi B; Saba A; Lucchesi S; Felipetto R; Danesi R; Francia G; Allegrini G; Falcone A; Bocci G
Invest New Drugs; 2016 Dec; 34(6):760-770. PubMed ID: 27557783
[TBL] [Abstract][Full Text] [Related]
11. The changing therapeutic landscape of castration-resistant prostate cancer.
Yap TA; Zivi A; Omlin A; de Bono JS
Nat Rev Clin Oncol; 2011 Aug; 8(10):597-610. PubMed ID: 21826082
[TBL] [Abstract][Full Text] [Related]
12. Is there a role for chemotherapy in prostate cancer?
Canil CM; Tannock IF
Br J Cancer; 2004 Sep; 91(6):1005-11. PubMed ID: 15150548
[TBL] [Abstract][Full Text] [Related]
13. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
Fujii Y; Kawakami S; Masuda H; Kobayashi T; Hyochi N; Kageyama Y; Kihara K
BJU Int; 2006 Jun; 97(6):1184-9. PubMed ID: 16686709
[TBL] [Abstract][Full Text] [Related]
14. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
[TBL] [Abstract][Full Text] [Related]
15. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy.
Hirano D; Minei S; Kishimoto Y; Yamaguchi K; Hachiya T; Yoshida T; Yoshikawa T; Endoh M; Yamanaka Y; Yamamoto T; Satoh Y; Ishida H; Okada K; Takimoto Y
Urol Int; 2005; 75(1):43-9. PubMed ID: 16037707
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT).
Cho D; Di Blasio CJ; Rhee AC; Kattan MW
Urol Oncol; 2003; 21(4):282-91. PubMed ID: 12954499
[TBL] [Abstract][Full Text] [Related]
17. The patient with hormone-refractory prostate cancer: determining who, when, and how to treat.
Kent EC; Hussain MH
Urology; 2003 Dec; 62 Suppl 1():134-40. PubMed ID: 14747051
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen levels and prognosis in patients with hormone-refractory prostate cancer treated with low-dose dexamethasone.
Morioka M; Kobayashi T; Furukawa Y; Jo Y; Shinkai M; Matsuki T; Yamamoto T; Tanaka H
Urol Int; 2002; 68(1):10-5. PubMed ID: 11803262
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
